| Literature DB >> 15725479 |
Yasufumi Kikuchi1, Shinsuke Uno, Yasuko Kinoshita, Yasushi Yoshimura, Shin-Ichiro Iida, Yuji Wakahara, Masayuki Tsuchiya, Hisafumi Yamada-Okabe, Naoshi Fukushima.
Abstract
Multiple myeloma is currently considered incurable despite the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation support. Here, we show antitumor efficacy of a novel bivalent single-chain antibody fragment (scFv) against CD47 in an in vivo myeloma model. We generated two types of novel scFv molecules against CD47 having apoptosis-inducing activity for leukemic cell lines: a non-covalently linked scFv dimer (diabody) and a covalently linked bivalent scFv. Administration of these bivalent scFvs significantly prolonged the survival of mice transplanted with KPMM2 human myeloma cells. Because bivalent scFvs induced neither ADCC nor CDC, such antitumor activity by bivalent scFv is presumably attributable to cell death caused by the ligation of CD47. Thus, these apoptosis-inducing scFvs will be effective as a novel therapy for multiple myeloma which is considered incurable with conventional therapy.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15725479 DOI： 10.1016/j.leukres.2004.09.005
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156